Acumen Pharmaceuticals outlines ALTITUDE AD Phase 2 plans and late 2026 data timeline
Q4 2024 Management View CEO Dan O’Connell highlighted the completion of enrollment for the ALTITUDE AD Phase 2 trial, with 542 participants enrolled in under 10 months. The study focuses on the ...
Princeton University1d
High Altitude: Acclimatization and Illnesses
Traveling at high altitude can be hazardous. The information provided here is designed for educational use only and is not a substitute for specific training or experience. Princeton University and ...
Acumen Pharmaceuticals Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer ...
Seeking Alpha2d
Acumen Pharmaceuticals outlines ALTITUDE AD Phase 2 plans and late 2026 data timeline
Management expects topline results from the ALTITUDE AD Phase 2 trial in late 2026, focusing on primary endpoints such as the Integrated Alzheimer’s Disease Rating Scale (iADRS) and secondary ...